Technologies | Sterling Pharma Solutions Skip to content
  • Services
    • API Development
    • API Manufacturing
    • Chemistry, Manufacturing and Controls (CMC)
    • Drug product testing
  • Material Science
    • Solid State Chemistry
    • Milling and Micronisation
  • Technologies
    • Hazardous Chemistry
    • Diazomethane
    • Hazard Evaluation
    • Chiral
    • Controlled Substances
    • Continuous Processing
    • Biocatalysis
    • Highly Potent API (HPAPI)
  • Knowledge Hub
    • All Resources
    • Articles
    • Downloads
    • Podcasts
    • Videos
    • About
    • Sign Up
  • Compliance
    • Quality
    • Health, Safety & Environment
  • About Sterling
    • Our Facilities
    • Our Approach
    • Partnership Development and Manufacturing Organisation (PDMO)
    • Our Heritage
    • Management Team
  • Latest News
  • Careers
  • Contact
Mail Menu
  • Latest News
  • Careers
  • Contact
Sterling Pharma Solutions
  • Services
    • API Development
    • API Manufacturing
    • Chemistry, Manufacturing and Controls (CMC)
    • Drug product testing
  • Material Science
    • Solid State Chemistry
    • Milling and Micronisation
  • Technologies
    • Hazardous Chemistry
    • Diazomethane
    • Hazard Evaluation
    • Chiral
    • Controlled Substances
    • Continuous Processing
    • Biocatalysis
    • Highly Potent API (HPAPI)
  • Knowledge Hub
    • All Resources
    • Articles
    • Downloads
    • Podcasts
    • Videos
    • About
    • Sign Up
  • Compliance
    • Quality
    • Health, Safety & Environment
  • About Sterling
    • Our Facilities
    • Our Approach
    • Partnership Development and Manufacturing Organisation (PDMO)
    • Our Heritage
    • Management Team
  • Hazardous Chemistry
  • Highly Potent API (HPAPI)
  • Biocatalysis
  • Chiral
  • Continuous Processing
  • Controlled Substances

Technologies

Scroll for content

Technology and Innovation programme

We have developed a Technology and Innovation Programme that allows us and our partners to explore the commercial viability and practical application of new technologies in the pharmaceutical industry.

Our programme complements our existing projects with a number of universities in the UK and aims to develop new partnerships with academic institutes and tech companies to explore new technologies and develop innovative solutions to API development and manufacturing challenges.

The programme is already supporting our work in hazard evaluation and process design, hazardous and chiral chemistry and continuous processing.

We are exploring opportunities around bio-catalysis, flow chemistry, chiral chemistry, fluorinations and hazardous chemistry techniques including the use of diazomethane (DAM).

  • Hazardous Chemistry

  • Highly Potent API

    Highly Potent API (HPAPI)

  • Hazard Evaluation

  • Diazomethane

  • Biocatalysis

  • Chiral

  • Controlled Substances

  • Continuous Processing

Controlled Substances
Continuous Processing
Chiral
Biocatalysis
Hazardous Chemistry
Highly Potent API (HPAPI)

You may also be interested in

  • Germantown, Wisconsin, US

Contact Us

UK Dudley
Sterling Place, Dudley
Cramlington
Northumberland
NE23 7QG
United Kingdom

Dudley, UK telephone:
+44 (0) 191 250 0471

US Germantown
WI32 N 10550 Grant Drive
Germantown,
WI 53022
USA

Germantown, US telephone:
+1 262 251 5044

US Cary
Sterling Pharma USA, LLC
1001 Sheldon Drive,
Suite 101
Cary, NC-27513
USA

Cary, US telephone:
+1 (919) 678 0702

Make an enquiry

Explore

  • About Sterling
  • API Development
  • API Manufacturing
  • Technologies
  • Our Facilities
  • Latest News
  • Careers
  • Knowledge Hub
  • All Resources
  • Articles
  • Downloads
  • Podcasts
  • Videos
  • About
  • Sign Up

Sterling Pharma Solutions Limited. Registration number: 05712796
Registered office address: Sterling Place, Dudley, Cramlington, Northumberland NE23 7QG Registered in England.

  • Legal
  • Gender Pay Gap
  • Privacy
  • Sitemap

Sign up to view this exclusive content and for insights into the latest pharma industry and CDMO trends.

Opt In

Sign up to view this exclusive content and for insights into the latest pharma industry and CDMO trends.